

doi: 10.13241/j.cnki.pmb.2014.10.032

缬沙坦联合吡格列酮治疗早期糖尿病肾病的疗效观察

王晓敏 刘庆华 屠叶平 张 婷 周丽英

(上海市奉贤区中心医院内分泌科 上海 201400)

摘要 目的:观察缬沙坦联合吡格列酮治疗早期糖尿病肾病的疗效及其对肾功能和氧化应激水平的影响。**方法:**选取 2010 年 1 月~2012 年 6 月在我院就诊的早期糖尿病肾病患者 90 例,随机分为观察组和对照组,每组各 45 例。对照组予以吡格列酮治疗,观察组在对照组的基础上予以缬沙坦治疗。观察两组治疗前后的尿白蛋白排泄率(UAER)、 β_2 微球蛋白(β_2 -MG)、血肌酐(SCr)、还原型谷胱甘肽(GSH)、丙二醛(MDA)和超氧化物歧化酶(SOD)活性水平的变化。**结果:**观察组和对照组的总有效率分别为 93.33%、75.56%,观察组显著高于对照组,差异有统计学意义($X^2=4.145$, $P=0.042$)。治疗后,两组患者的 UAER、 β_2 -MG、SCr 和 MDA 水平均较治疗前明显降低($P<0.01$),且观察组以上指标的水平显著低于对照组($P<0.01$);而两组 SOD 和 GSH 水平均较治疗前明显升高($P<0.01$),且观察组以上指标的水平显著高于对照组,差异有统计学意义($P<0.01$)。**结论:**缬沙坦联合吡格列酮治疗早期糖尿病肾病的疗效较单用吡格列酮更好,并可显著改善患者的肾功能和降低氧化应激水平。

关键词:缬沙坦;吡格列酮;糖尿病肾病;氧化应激;疗效

中图分类号:R587.2 文献标识码:A 文章编号:1673-6273(2014)10-1935-03

Efficacy of Valsartan Combined with Pioglitazone in the Patients with Early Diabetic Nephropathy

WANG Xiao-min, LIU Qing-hua, TU Ye-ping, ZHANG Ting, ZHOU Li-ying

(Department of endocrine, Fexian District Central Hospital, Shanghai, 201400, China)

ABSTRACT Objective: To observe the efficacy of valsartan combined with pioglitazone in the treatment of patients with early diabetic nephropathy and its impact on the renal function and oxidative stress. **Methods:** 90 patients with early diabetic nephropathy, from January 2010 to June 2012, were randomly divided into the observation group and control group, 45 cases in each group. The control group was treated by pioglitazone alone, while the observation group was given valsartan on the basis of control group. The urinary albumin excretion rate (UAER), β_2 -microglobulin (β_2 -MG), serum creatinine (SCr), reduced glutathione (GSH), malondialdehyde (MDA) and super oxide dismutase (SOD) were observed before and after treatment. **Results:** The total effective rate of observation group and control group were respectively 93.33%, 75.56%, which was significantly higher in the observation group ($X^2=4.145$, $P=0.042$). After treatment, the levels of UAER, β_2 -MG, SCr and MDA in both groups were significantly lower than those before treatment ($P<0.01$), which were significantly lower in the observation group than those of the control group ($P<0.01$). However, the levels of SOD and GSH significantly increased in both groups compared with those before treatment ($P<0.01$), which were significantly higher in the observation group than those of the control group ($P<0.01$). **Conclusion:** The treatment of valsartan combined with pioglitazone was more effective to the patients with early diabetic nephropathy than pioglitazone alone, which significantly improved the kidney function and relieved the oxidative stress.

Key words: Valsartan; Pioglitazone; Diabetic nephropathy; Oxidative stress; Efficacy

Chinese Library Classification(CLC): R587.2 **Document code:** A

Article ID: 1673-6273(2014)10-1935-03

糖尿病肾病是糖尿病患者的常见并发症之一,早期诊断和治疗糖尿病肾病是改善糖尿病患者预后的关键^[1-4]。缬沙坦通过阻断肾素-血管紧张素-醛固酮系统(RAAS)的药物有效降低尿蛋白水平^[5-7],起保护肾脏的作用,其降低蛋白的作用独立于降压作用,在临床上已经取得较好的疗效。吡格列酮为高度选择性和高效的二型受体 γ (PPAR- γ)的激动剂,其主要功能是改善胰岛 β 细胞功能,降低机体的胰岛素抵抗,从而达到治疗糖

尿病的作用^[8-9]。临床研究表明吡格列酮降低糖尿病肾病患者的尿蛋白,保护肾功能,其机理可能与吡格列酮可以降低机体的骨桥蛋白有关^[10],其确切的机理尚不清楚。我院采用缬沙坦联合吡格列酮治疗早期糖尿病肾病取得了良好的疗效,现报告如下。

1 临床资料与方法

1.1 临床资料

选取 2010 年 1 月~2012 年 6 月在我院就诊的早期糖尿病肾病患者 90 例,其中男 47 例,女 43 例,平均年龄 $55.76 \pm 10.43(45 \sim 75)$ 岁,平均病程 $9.76 \pm 2.87(4 \sim 19)$ 年。纳入标准:均为 2 型糖尿病患者,符合早期糖尿病肾病诊断标准;均知情同意。

作者简介:王晓敏(1981-),女,主治医师,大学本科,从事糖尿病肾病的早期预防及治疗的研究, E-mail: 15921300758@126.com

(收稿日期:2013-11-15 接受日期:2013-12-12)

排除标准:糖尿病合并其他严重的并发症;合并重要脏器如心肺肝脑等的损害;有高血压,冠心病,感染性疾病和肿瘤等慢性疾病;近期接受血管紧张素转化酶抑制剂(ACEI)或血管紧张素Ⅱ受体拮抗剂(ARB)治疗的患者。将患者按照随机数字法分为观察组和对照组,两组各45例,两组的年龄、性别、病程等一般资料比较差异无统计学意义($P>0.05$),具有可比性。

1.2 方法

1.2.1 治疗方法 两组均予以控制血糖和血压,调节血脂,抗感染、改善微循环,纠正水电解质紊乱和餐前30min口服吡格列酮,30mg/次,1次/d的常规治疗。观察组在上述的基础上予以缬沙坦80mg口服,1次/d,2周为一个疗程。

1.2.2 标本的保存 治疗前和治疗后2周分别抽取空腹肘静脉血3mL,注入普通塑料管内,1.8mL注入含0.2mL 3.8%枸橼酸钠的抗凝管内,标本采集后1h内3000r/min,离心10min,将血清或血浆提取后分别分装于0.5mL的EP管内,-30℃保存,1个月内检测。

1.2.3 疗效评定标准 显效:治疗疗程结束后,尿蛋白定量下降幅度 $>50\%$;有效:尿蛋白定量下降幅度在 $20\% \sim 50\%$ 之间;无效:下降幅度 $<20\%$ 。

1.2.4 观察指标和检测方法 ①尿液指标:尿白蛋白排泄率(UAER)、尿 β_2 微球蛋白(β_2 -MG)采用放免分析法,24h尿蛋白定量采用双缩脲法;②生化指标:血肌酐(SCr)采用全自动生化分析仪测定,糖化血红蛋白采用微粒色谱法。还原型谷胱甘肽(GSH)测定采用二硫代硝基苯甲酸比色法(DNTB法),丙二醛(MDA)测定采用硫代巴比妥酸(TBA)法。超氧化物歧化酶(SOD)活力测定采用黄嘌呤氧化酶法。

1.3 统计学处理

采用SPSS19.0软件,计量资料以均数 $\pm$ 标准差($\bar{X} \pm S$)表示,两组间比较采用t检验,治疗前后比较,采用配对t检验。计数资料采用率表示,两两比较采用 χ^2 检验,以 $P<0.05$ 为差异有统计学意义。

2 结果

2.1 两组临床疗效的比较

从表1可知,观察组45例患者中,30例显效,12例有效,治疗总有效率为93.33%,而对照组45例患者中,21例显效,13例有效,治疗总有效率为75.56%,观察组显著高于对照组($\chi^2=4.145$, $P=0.042$)。

表1 两组治疗疗效的比较(例)

Table 1 Comparison of the clinical effect rate between the two groups after treatment (cases)

Group	Cases	Excellence	Good	Invalid	Total efficiency(%)
Observation group	45	30	12	3	93.33
Control group	45	21	13	11	75.56

2.2 两组治疗前后UAER、 β_2 -MG和SCr水平的比较

从表2可知,治疗后,两组UAER、 β_2 -MG和SCr水平均

较治疗前明显降低($P<0.01$),且观察组较对照组更低($P<0.01$)。

表2 两组治疗前后UAER、 β_2 -MG和SCr水平的比较($\bar{x} \pm s$)

Table 2 Comparison of the serum levels of UAER, β_2 -MG and SCr between two groups before and after treatment($\bar{x} \pm s$)

Group	Cases	UAER($\mu\text{g/mL}$)		β_2 -MG(mmol/mL)		SCr($\mu\text{mol/mL}$)	
		Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment
Observation group	45	278.32 $\pm$ 29.65	135.65 $\pm$ 19.64	34.26 $\pm$ 9.24	23.65 $\pm$ 7.68	136.57 $\pm$ 9.67	115.67 $\pm$ 8.64
Control group	45	271.35 $\pm$ 35.24	223.84 $\pm$ 24.35	33.94 $\pm$ 8.51	29.64 $\pm$ 6.64	134.94 $\pm$ 6.97	124.67 $\pm$ 9.37
t		1.015	18.911	0.171	3.958	0.917	4.737
p		0.313	0.000	0.865	0.000	0.362	0.000

注:与治疗前比较,* $P<0.05$,** $P<0.01$ 。

Note: Compared with that before treatment, * $P<0.05$, ** $P<0.01$.

表3 两组治疗前后MDA、SOD和GSH水平的比较($\bar{x} \pm s$)

Table 3 Comparison of the serum levels of MDA, SOD and GSH between two groups before and after treatment($\bar{x} \pm s$)

Group	Cases	MDA(nmol/mL)		SOD(mg/L)		GSH(mg/L)	
		Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment
Observation group	45	7.83 $\pm$ 1.38	5.37 $\pm$ 1.82	55.27 $\pm$ 12.73	87.43 $\pm$ 12.93	178.32 $\pm$ 26.32	220.73 $\pm$ 32.83
Control group	45	7.79 $\pm$ 1.26	4.19 $\pm$ 1.68	56.04 $\pm$ 11.35	75.32 $\pm$ 10.47	175.22 $\pm$ 28.81	198.46 $\pm$ 29.49
t		0.144	3.196	0.303	4.883	0.533	3.385
p		0.886	0.002	0.763	0.000	0.595	0.001

注:与治疗前比较,* $P<0.05$,** $P<0.01$ 。

Note: Compared with that before treatment, * $P<0.05$, ** $P<0.01$.

2.3 两组治疗前后 MDA、SOD 和 GSH 水平的比较

治疗后,两组 MDA 水平均较治疗前明显降低($P<0.01$),而 SOD 和 GSH 水平明显升高($P<0.01$),且观察组 MDA 水平较对照更低, SOD 和 GSH 水平较对照组更高 ($P<0.01$)。

3 讨论

糖尿病肾病重要的病理生理基础为各种致病因素导致血管紧张素 II(AT)分泌增多,引起机体的水钠潴留,肾脏系膜细胞的增生肥大,使肾脏细胞外基质增厚,肾小球滤过膜的通透性增高,最终导致蛋白尿的产生^[1]。

吡格列酮为高度选择性和高效的二型受体 γ (PPAR- γ)的激动剂,其主要功能是改善胰岛 β 细胞功能,降低机体的胰岛素抵抗,增加机体对胰岛素的敏感性,从而降低机体的血糖水平^[12,13]。同时,其可以促进肾小球基底膜蛋白多糖的合成,可以减少肾小球对蛋白的滤过作用,抑制肾小球基底膜和系膜的增生^[14,15]。缬沙坦可以选择性地作用于 AT-1 受体,阻断血管紧张素 II 与 AT-1 受体的结合,从而抑制血管收缩和醛固酮的释放,产生降压作用^[16,17]。此外,缬沙坦对于阻断肾小球毛细血管的膜压升高、蛋白尿的形成具有良好的效果,可避免肾小球硬化和间质纤维化的发生^[18]。本组研究表明吡格列酮联合缬沙坦治疗早期糖尿病肾病的总有效率为 93.33%, 显著高于吡格列酮单一治疗,且患者的肾功能显著改善。

现有研究表明,糖尿病肾病的发病与氧化应激有关,糖尿病肾病患者的抗氧化能力下降,机体处于氧化应激状态,大量的葡萄糖及其代谢产物被氧化,产生大量的自由基,使肾小球的基底膜脂质过氧化并受损,肾小球的滤过功能发生改变^[19]。由于氧化应激状态导致 $\text{Na}^+\text{-K}^+\text{-ATP}$ 酶活性下降,导致肾小球重吸收功能发生障碍,最终导致糖尿病肾病的发生^[20,21]。本组研究表明,治疗后,吡格列酮联合缬沙坦治疗早期糖尿病肾病患者的 MDA 水平较单用吡格列酮明显降低,而 SOD 和 GSH 水平明显升高。这可能是因为缬沙坦联合吡格列酮治疗可以促进机体 SOD 和 GSH 的增加,而 MDA 水平明显下降,使机体对氧自由基的清除增加,降低机体的氧化能力,缓解糖尿病肾病的氧化应激状态,改善肾小球血管基底膜,系膜细胞和细胞外基质,促进肾小球的滤过,增加对蛋白的重吸收,从而达到缓解糖尿病肾病的作用。

总之,缬沙坦联合吡格列酮治疗早期糖尿病肾病的疗效较单用吡格列酮更好,具有更好的降低尿蛋白和提高机体的 SOD 及 GSH 水平,具有显著改善患者的肾功能和降低氧化应激作用。

参考文献(References)

- [1] Berger M, Monks D, Wanner C, et al. Diabetic nephropathy: an inherited disease or just a diabetic complication? [J]. *Kidney Blood Press Res*, 2003, 26(3):143-154
- [2] Alter M L, Kretschmer A, Von Websky K, et al. Early urinary and plasma biomarkers for experimental diabetic nephropathy [J]. *Clin Lab*, 2012, 58(7-8):659-671
- [3] Cetin E, Civelek S, Andican G, et al. Plasma AGE-peptides and C-peptide in early-stage diabetic nephropathy patients on thiamine and pyridoxine therapy [J]. *Minerva Med*, 2013, 104(1):93-102
- [4] Gheissari A, Javanmard S H, Shirzadi R, et al. The effects of blocking Angiotensin receptors on early stages of diabetic nephropathy [J]. *Int J Prev Med*, 2012, 3(7):477-482
- [5] Locatelli F, Palmer B F, Kashihara N, et al. Renal protective effect of RAAS blockade across the renal continuum, with a review of the efficacy and safety of valsartan [J]. *Curr Med Res Opin*, 2009, 25(12):2933-2949
- [6] Chrysant S G. The antihypertensive effectiveness and safety of dual RAAS blockade with aliskiren and valsartan [J]. *Drugs Today (Barc)*, 2010, 46(3):151-162
- [7] Periard D, Rey M A, Casagrande D, et al. The effect of valsartan versus non-RAAS treatment on autoregulation of cerebral blood flow [J]. *Cerebrovasc Dis*, 2012, 34(1):78-85
- [8] Thal S C, Heinemann M, Luh C, et al. Pioglitazone reduces secondary brain damage after experimental brain trauma by PPAR- γ -independent mechanisms [J]. *J Neurotrauma*, 2011, 28(6):983-993
- [9] Subramanian V, Golledge J, Ijaz T, et al. Pioglitazone-induced reductions in atherosclerosis occur via smooth muscle cell-specific interaction with PPAR $\{\gamma\}$ [J]. *Circ Res*, 2010, 107(8):953-958
- [10] Yan X, Sano M, Lu L, et al. Plasma concentrations of osteopontin, but not thrombin-cleaved osteopontin, are associated with the presence and severity of nephropathy and coronary artery disease in patients with type 2 diabetes mellitus [J]. *Cardiovasc Diabetol*, 2010, 9:70
- [11] Najafian B, Alpers C E, Fogo A B. Pathology of human diabetic nephropathy [J]. *Contrib Nephrol*, 2011, 170:36-47
- [12] Nakatsuji H, Kishida K, Kobayashi H, et al. Three-month treatment with pioglitazone reduces circulating C1q-binding adiponectin complex to total-adiponectin ratio, without changes in body mass index, in people with type 2 diabetes [J]. *Diabetes Res Clin Pract*, 2013, 99(1):e14-e17
- [13] Pei Q, Huang Q, Yang G P, et al. PPAR- γ 2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China [J]. *Acta Pharmacol Sin*, 2013, 34(2):255-261
- [14] Elrashidy R A, Asker M E, Mohamed H E. Beneficial effects of pioglitazone against cardiovascular injury are enhanced by combination with aliskiren in a rat model of diabetic nephropathy [J]. *J Pharm Pharmacol*, 2012, 64(6):862-871
- [15] Elrashidy R A, Asker M E, Mohamed H E. Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy [J]. *J Cardiovasc Pharmacol Ther*, 2012, 17(3):324-333
- [16] Jiao B, Zhang Y H, Cheng Y N, et al. A low-dose combination of valsartan and low molecular weight heparin better improved glomerular permeability than did high-dose monotherapy in rats with diabetic nephropathy [J]. *Drug Discov Ther*, 2011, 5(3):119-124
- [17] Dong Y F, Liu L, Lai Z F, et al. Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice [J]. *J Hypertens*, 2010, 28(7):1554-1565
- [18] Zhao L S, Bai W W, Xiang G D, et al. Clinical evaluation of valsartan and metoprolol tartrate in treatment of diabetic nephropathy with positive beta1-adrenergic and anti-angiotensin II type 1 receptor antibody [J]. *Chin Med J (Engl)*, 2012, 125(19):3543-3547
- [19] Miraghajani M S, Esmailzadeh A, Najafabadi M M, et al. Soy milk consumption, inflammation, coagulation, and oxidative stress among type 2 diabetic patients with nephropathy [J]. *Diabetes Care*, 2012, 35(10):1981-1985
- [20] Singh D K, Winocour P, Farrington K. Oxidative stress in early diabetic nephropathy: fueling the fire [J]. *Nat Rev Endocrinol*, 2011, 7(3):176-184
- [21] Kashihara N, Haruna Y, Kondeti V K, et al. Oxidative stress in diabetic nephropathy [J]. *Curr Med Chem*, 2010, 17(34):4256-4269